First CRISPR Sickle Cell Patient ‘Reborn’: FDA Approval Expected
FDA soon rules if gene-editing CRISPR drug Exa-cel can be used commercially to treat sickle cell disease, opening door to many other therapies.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Ellen Matloff, Contributor Tags: Healthcare /healthcare Innovation /innovation Editors' Pick editors-pick business pharma & standard Source Type: news